What question did this study set out to answer?

To evaluate the prognostic significance of monocarboxylate transporter 1 (MCT1) and monocarboxylate transporter 4 (MCT4) expression in small bowel neuroendocrine tumors.

May 22, 2022CancersOpen Access

Monocarboxylate Transporters 1 and 4 and Prognosis in Small Bowel Neuroendocrine Tumors

View Full Paper

Ask AI

Bookmark

Authors

NHNiko HiltunenOulu University Hospital JRJukka RintalaOulu University Hospital JVJuha P. VäyrynenOulu University Hospital

Discussion

Member takes

Implication

Cohort study reveals elevated monocarboxylate transporter 4 expression improves disease-specific survival in small bowel neuroendocrine tumors, indicating its potential value as a prognostic...

Key Points

To evaluate the prognostic significance of monocarboxylate transporter 1 (MCT1) and monocarboxylate transporter 4 (MCT4) expression in small bowel neuroendocrine tumors.
Analyzed tumor specimens from 109 primary small bowel neuroendocrine tumors and 61 matched lymph node metastases across two Finnish hospitals.
Performed immunohistochemical staining for MCT1 and MCT4, scoring tumors (0, 1, or 2) based on staining intensity and percentage of positive cells.
Assessed disease-specific survival using Kaplan–Meier survival analysis and multivariable Cox proportional hazards regression models.
High MCT4 staining intensity was associated with significantly superior disease-specific survival compared to low intensity (85.7% vs. 56.6%, p = 0.020).
MCT4 scores of 0, 1, and 2 corresponded to disease-specific survival rates of 52.8%, 58.8%, and 100% (p = 0.025), with the lowest adjusted mortality hazard observed in patients with high MCT4 scores.
MCT1 expression demonstrated no statistically significant association with disease-specific survival.

Cite This Study

Hiltunen et al. (2022) studied this question.

synapsesocial.com/papers/6aaf7e327d52d73992ce9d99 https://doi.org/10.3390/cancers14102552

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reveals elevated monocarboxylate transporter 4 expression improves disease-specific survival in small bowel neuroendocrine tumors, indicating its potential value as a prognostic...

Monocarboxylate Transporters 1 and 4 and Prognosis in Small Bowel Neuroendocrine Tumors

Discussion

Member takes

Implication

Key Points

Cite This Study

Monocarboxylate Transporters 1 and 4 and Prognosis in Small Bowel Neuroendocrine Tumors

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider